Uptake of TEX by DCs in vivo.

Slides:

Advertisements

Similar presentations

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.

Advertisements

AF647-RIS is internalized by TAMs in vivo.

Synergistic antitumor effect of anti-CD40/CpG and 14

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Uptake of T-MPs for DC maturation and antigen presentation.

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.

Immunologic responses after the MN-mediated cancer immunotherapy.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Vascular HR ligand expression depends on tumor anatomical location.

DCs induce the proliferation of autologous T cells.

Resistance of CD141+ DCs to influenza virus in vivo in humanized mice.

APCs from hypertensive mice present antigens more efficiently.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

CD25+ proliferation and suppression are independent functional variables in type 1 diabetes. CD25+ proliferation and suppression are independent functional.

Exosome-mediated inhibition of T cells is reversible.

Dox titration and kinetic analyses of CD19CAR expression upon Dox administration and discontinuation. Dox titration and kinetic analyses of CD19CAR expression.

CT-26 colon cancer induces the recruitment of protumor mast cells and the accumulation of MDSCs. CT-26 colon carcinoma cells (2 × 105) were injected s.c.

Induction of apoptosis by NS398.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

PD-L1 expression by DC subsets from lesional CTCL and healthy skin.

GC reaction is impaired in NOTCH2 knock-in mice.

coTCRcys-transduced T cells control tumor growth in vivo.

Stereotactic radiotherapy increases Tregs in tumors.

Anti-CD20 CAR mRNA enhances exPBNK in vitro cytolytic activity against CD20+ B-NHL cells and rituximab-resistant cells. exPBNK were electroporated in the.

Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Matriptase-2 inhibited breast tumor development in vivo.

A, iDC (top) or mDC (bottom) were loaded with or without 10 pfu/cell reovirus, and cultured with Mel-888 cells in the presence of blocking serum. A, iDC.

Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.

Anti-Flk-1 mAb inhibits vascularization of Matrigel plugs.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Canonical but not adaptive NK-cell function is suppressed by Tregs.

RT-TEX induce activation and IFN-I production by primary DCs

Isolation and proteomic profiling of TEX

Effect of nivolumab or ipilimumab on immune responses to vaccination in cynomolgus monkeys. Effect of nivolumab or ipilimumab on immune responses to vaccination.

Systemic reovirus treatment targets disseminated human myeloma in vivo

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Trametinib and combination promote moDC maturation and decrease moDC viability. Trametinib and combination promote moDC maturation and decrease moDC viability.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Decreased dopamine uptake following downregulation of SLC6A3.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

MPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. mPD-L1–transfected 300 cells do not bind to mB7-1–transfected 300 cells. Cell-to-cell.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Activation status of NK cells is associated with therapeutic effects of TKIs. PBMCs from CML patients were cocultured with HLA class I–deficient K562 cells.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

MDSC population in patient peripheral blood.

EC-derived SP cells are targeted by CD30.CAR T cells.

WEE1 inhibition followed by TRAIL treatment results in apoptotic cell death in MB231 cells. WEE1 inhibition followed by TRAIL treatment results in apoptotic.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Varying the MHC-I affinity, TCR affinity or antigen dose alters the phenotype of CD8 T cells ex vivo. Varying the MHC-I affinity, TCR affinity or antigen.

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

Uptake of TEX by DCs in vivo. Uptake of TEX by DCs in vivo. PKH67-labeled TEX (10 μg) were injected s.c. at the base of the tail, and the DLNs were collected 24, 48, and 72 hours after injection (n = 3/group per time point). DLN cells were stained with anti-CD11c to identify DCs. A, Representative flow cytometry plots gated on CD11c+ DCs. Boxes encase PKH67+ DCs. B, Mean percentage ± SEM of TEX+ CD11c+ cells at different times postinjection. Using a Student two-tailed t test; *, P < 0.05. Julie M. Diamond et al. Cancer Immunol Res 2018;6:910-920 ©2018 by American Association for Cancer Research